Literature DB >> 12235311

Myopathy with antibodies to the signal recognition particle: clinical and pathological features.

T Miller1, M T Al-Lozi, G Lopate, A Pestronk.   

Abstract

OBJECTIVES: To study myopathies with serum antibodies to the signal recognition particle (SRP), an unusual, myositis specific antibody associated syndrome that has not been well characterised pathologically.
METHODS: Clinical, laboratory, and myopathological features were evaluated in seven consecutive patients with a myopathy and serum anti-SRP antibodies, identified over three years. The anti-SRP myopathy was compared with myopathology in other types of inflammatory and immune myopathies.
RESULTS: The patients with anti-SRP antibodies developed weakness at ages ranging from 32 to 70 years. Onset was seasonal (August to January). Weakness became severe and disability developed rapidly over a period of months. Muscle pain and fatigue were present in some patients. No patient had a dermatomyositis-like rash. Serum creatine kinase was very high (3000 to 25 000 IU/l). Muscle biopsies showed an active myopathy, including muscle fibre necrosis and regeneration. There was prominent endomysial fibrosis, but little or no inflammation. Endomysial capillaries were enlarged, reduced in number, and associated with deposits of the terminal components of complement (C5b-9, membrane attack complex). Strength improved in several patients after corticosteroid treatment.
CONCLUSIONS: Myopathies associated with anti-SRP antibodies may produce severe and rapidly progressive weakness and disability. Muscle biopsies show active myopathy with pathological changes in endomysial capillaries but little inflammation. Corticosteroid treatment early in the course of the illness is often followed by improvement in strength. In patients with rapidly progressive myopathies and a high serum creatine kinase but little inflammation on muscle biopsy, measurement of anti-SRP antibodies and pathological examination of muscle, including evaluation of endomysial capillaries, may provide useful information on diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12235311      PMCID: PMC1738058          DOI: 10.1136/jnnp.73.4.420

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  24 in total

1.  Autoantibody profiles in the sera of European patients with myositis.

Authors:  R Brouwer; G J Hengstman; W Vree Egberts; H Ehrfeld; B Bozic; A Ghirardello; G Grøndal; M Hietarinta; D Isenberg; J R Kalden; I Lundberg; H Moutsopoulos; P Roux-Lombard; J Vencovsky; A Wikman; H P Seelig; B G van Engelen ; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

2.  Clinical and serological aspects of patients with anti-Jo-1 antibodies--an evolving spectrum of disease manifestations.

Authors:  W A Schmidt; W Wetzel; R Friedländer; R Lange; H F Sörensen; H J Lichey; E Genth; R Mierau; E Gromnica-Ihle
Journal:  Clin Rheumatol       Date:  2000       Impact factor: 2.980

Review 3.  Inclusion body myositis: genetic factors, aberrant protein expression, and autoimmunity.

Authors:  A Oldfors; I M Fyhr
Journal:  Curr Opin Rheumatol       Date:  2001-11       Impact factor: 5.006

Review 4.  The signal recognition particle.

Authors:  R J Keenan; D M Freymann; R M Stroud; P Walter
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

Review 5.  Update on myositis-specific and myositis-associated autoantibodies.

Authors:  I N Targoff
Journal:  Curr Opin Rheumatol       Date:  2000-11       Impact factor: 5.006

Review 6.  Inflammatory muscle diseases.

Authors:  D Hilton-Jones
Journal:  Curr Opin Neurol       Date:  2001-10       Impact factor: 5.710

7.  Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres.

Authors:  T Mozaffar; A Pestronk
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

8.  Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies.

Authors:  P Englund; E Lindroos; I Nennesmo; L Klareskog; I E Lundberg
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

Review 9.  Paraneoplastic necrotizing myopathy: clinical and pathological features.

Authors:  M I Levin; T Mozaffar; M T Al-Lozi; A Pestronk
Journal:  Neurology       Date:  1998-03       Impact factor: 9.910

10.  Biogenesis of the signal recognition particle (SRP) involves import of SRP proteins into the nucleolus, assembly with the SRP-RNA, and Xpo1p-mediated export.

Authors:  H Grosshans; K Deinert; E Hurt; G Simos
Journal:  J Cell Biol       Date:  2001-05-14       Impact factor: 10.539

View more
  69 in total

1.  A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy.

Authors:  Lisa Christopher-Stine; Livia A Casciola-Rosen; Grace Hong; Tae Chung; Andrea M Corse; Andrew L Mammen
Journal:  Arthritis Rheum       Date:  2010-09

2.  Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series.

Authors:  Ritu Valiyil; Livia Casciola-Rosen; Grace Hong; Andrew Mammen; Lisa Christopher-Stine
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-09       Impact factor: 4.794

Review 3.  [Current treatments of dermatomyositis and polymyositis].

Authors:  J Richter; C Iking-Konert
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

Review 4.  Myositis-specific autoantibodies: detection and clinical associations.

Authors:  Sander H J van Dooren; Walther J van Venrooij; Ger J M Pruijn
Journal:  Auto Immun Highlights       Date:  2011-03-23

Review 5.  The utility of muscle biopsy.

Authors:  David Lacomis
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

Review 6.  The evolving spectrum of polymyositis and dermatomyositis--moving towards clinicoserological syndromes: a critical review.

Authors:  Sarah Tansley; Harsha Gunawardena
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 7.  Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies.

Authors:  Leandro Ladislau; Louiza Arouche-Delaperche; Yves Allenbach; Olivier Benveniste
Journal:  Curr Rheumatol Rep       Date:  2018-08-03       Impact factor: 4.592

8.  Autoantibodies and their significance in myositis.

Authors:  Ira N Targoff
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

9.  [Therapy of myositis].

Authors:  A D Keck; U A Walker
Journal:  Z Rheumatol       Date:  2013-04       Impact factor: 1.372

10.  Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.

Authors:  Puja Srivastava; Sanjay Dwivedi; Ramnath Misra
Journal:  Rheumatol Int       Date:  2016-05-14       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.